Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
Toshio Tanaka,1,2 Yoshihiro Hishitani,3 Atsushi Ogata2,3 1Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan; 2Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan; 3Departme...
Guardado en:
Autores principales: | Tanaka T, Hishitani Y, Ogata A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4cfc7dfb526d47ab9d4647b8a2a29caf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Review of tocilizumab in the treatment of rheumatoid arthritis
por: Yasuaki Okuda
Publicado: (2008) -
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
por: Masahiko Mihara, et al.
Publicado: (2011) -
Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis
por: Paula FS, et al.
Publicado: (2013) -
Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.
por: Sho Mokuda, et al.
Publicado: (2013) -
Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid M, et al.
Publicado: (2011)